查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1511820

美國外分泌胰臟功能不全診斷市場規模、佔有率和趨勢分析報告：按診斷方法、最終用途和細分市場預測，2024-2030 年

U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Size, Share & Trends Analysis Report By Diagnostic Method (Laboratory Tests, Imaging Tests), By End-use (Hospitals, Clinics, Diagnostic Laboratories), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 85 Pages | 商品交期: 2-10個工作天內

價格

美國外分泌胰臟功能不全診斷市場的成長與趨勢

Grand View Research最新報告顯示，到2030年，美國外分泌胰臟功能不全診斷的市場規模預計將達到23.9億美元，2024年至2030年複合年成長率為7.04%。

有幾個因素正在推動市場成長，例如胰臟疾病盛行率的增加、技術進步以及有利的政府舉措和資金。該行業未來的一個關鍵趨勢是將機器學習演算法和人工智慧 (AI) 與診斷工具整合。例如，胃腸病學人工智慧平台等基於人工智慧的軟體平台可以分析來自電腦斷層掃描和 MRI 的醫學影像資料，以幫助醫療專業人員更準確、更有效地識別胰臟功能不全的徵兆。此類技術趨勢預計將在未來提高診斷準確性、減少解釋錯誤並改善患者治療結果，從而推動預測期內的產品需求。

隨著市場競爭變得更加激烈，消費者對改進的高產量、可靠的診斷設備和耗材的需求從未如此強烈。 電腦斷層掃描和 MRI 中的人工智慧等新時代技術預計將擾亂傳統產品的銷售，並在市場上開闢新的研發機會。價格、相容性、安全性和獲得結果的時間是區分新 EPI 測試技術與現有 EPI 測試技術的關鍵因素，從而賦予它們競爭優勢。例如，ALPCO Diagnostics 推出了最先進的測試，包括胰臟彈性蛋白酶 (PE)化學冷光ELISA 和 CLIA 測試，旨在快速準確地檢測糞便中的胰臟彈性蛋白酶。這些先進的檢測方法為醫療保健專業人員提供了診斷 EPI 的可靠方法，有助於快速介入並改善患者的治療結果。然而，公司正專注於開發功效更高、成本更低的新產品。

美國胰臟外分泌功能不全診斷市場報告亮點

  • 根據診斷方法，實驗室檢測產業在 2023 年佔據了最大的收益佔有率。實驗室檢查包括間接胰臟功能檢查和其他檢查，如胰臟炎基因檢測（如遺傳性胰臟炎基因組）和13C混合三酸甘油酯呼吸檢測，以診斷患者的外分泌胰臟功能不全。
  • 另一方面，包括血液檢測和糞便檢驗在內的間接胰臟功能檢測領域預計在預測期內將以顯著的複合年成長率成長。
  • 根據最終用途，醫院和診所部門在 2023 年佔據最大的收益佔有率。
  • 全國範圍內強大的醫院和診所網路以及擁有熟練診斷嚴重 EPI 的工作人員是醫院和診所成為診斷和治療首選的主要因素。
  • 市場的併購活動處於低至中等水平，顯示競爭格局穩定，注重內部發展而非外部整合。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章美國外分泌胰臟功能不全診斷市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國胰臟外分泌功能不全診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
  • 監管場景
  • 退款場景
  • 價格分析
  • 目標人口分析

第4章美國外分泌胰臟功能不全診斷市場：診斷方法的估計與趨勢分析

  • 美國外分泌胰臟功能不全診斷市場：診斷方法細分儀表板
  • 美國外分泌胰臟功能不全診斷市場：診斷方法變化分析
  • 2018-2030年美國胰臟外分泌功能不全診斷市場規模及趨勢分析（依診斷方法）
  • 臨床檢查
  • 影像檢查

第5章美國外分泌胰臟功能不全診斷市場：依最終用途分類的估計與趨勢分析

  • 美國外分泌胰臟功能不全診斷市場：最終用途細分儀表板
  • 美國外分泌胰臟功能不全診斷市場：最終用途變異分析
  • 2018-2030年美國外分泌胰臟功能不全診斷市場規模與趨勢分析（依最終用途）
  • 醫院/診所
  • 診斷實驗室
  • 研究機構

第6章 競爭狀況

  • 參與企業分類
  • 參與企業概況
  • 財務績效
  • 產品基準
  • 熱圖分析
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 消費行為分析
    • ChiRhoClin
    • Certest Biotec.
    • ScheBo Biotech AG
    • Immundiagnostik AG
    • Laboratory Corporation of America Holdings
    • Boster Biological Technology
    • ALPCO Diagnostics
    • Quest Diagnostics Incorporated
    • DiaSorin SpA
    • ARUP Laboratories
    • Alpha Laboratories
    • Verisana Laboratories
Product Code: GVR-4-68040-299-1

U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Growth & Trends:

The U.S. exocrine pancreatic insufficiency diagnostics market size is expected to reach USD 2.39 billion by 2030, growing at a CAGR of 7.04% from 2024 to 2030, according to a new report by Grand View Research, Inc. Several factors are driving market growth, including increasing incidence of pancreatic diseases, technological advancements, and favorable government initiatives & funding. A key future trend in the industry is the integration of machine learning algorithms and Artificial Intelligence (AI) with diagnostic tools. For instance, AI-based software platforms like the gastroenterology-AI platform analyze medical imaging data from CT scans or MRIs to assist healthcare professionals in identifying signs of pancreatic insufficiency more accurately and efficiently. This technological trend is expected to enhance diagnostic accuracy, reduce interpretation errors, and improve patient outcomes in the future, thereby driving the demand for products over the forecast period.

As the market becomes increasingly competitive, consumer needs are at an all-time high for improved diagnostic instruments and consumables in terms of high yield & robust outcomes. New-age technologies, such as AI in CT scans and MRIs, are expected to impede the sales of older products, opening new R&D opportunities in the market. Price, compatibility, safety, and time taken to provide results are major factors differentiating new EPI testing technologies from existing ones, thereby gaining a competitive edge over them. For instance, ALPCO Diagnostics introduces state-of-the-art assays, including the Pancreatic Elastase (PE) Chemiluminescence ELISA and CLIA tests, designed to detect pancreatic elastase rapidly & accurately in the stool. These advanced assays offer healthcare professionals a reliable means of diagnosing EPI, facilitating prompt intervention and improved patient outcomes. However, companies are focusing on developing newer products with higher efficacy made available at lower costs.

U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Report Highlights:

  • Based on diagnostic method, the laboratory tests segment accounted for the largest revenue share in 2023. Laboratory tests include indirect pancreatic function tests and other tests such as genetic testing for pancreatitis (such as Hereditary Pancreatitis Gene Panel) and 13C-mixed triglyceride breath tests for diagnosing exocrine pancreatic insufficiency in patients.
  • On the other hand, the indirect pancreatic function test segment, which includes blood tests and stool tests, is expected to grow at a significant CAGR during the forecast period.
  • Based on end-use, the hospitals and clinics segment accounted for the largest revenue share in 2023.
  • The presence of a strong network of hospitals & clinics throughout the country and the availability of skilled staff for diagnosing severe EPI are some of the key factors responsible for the high preference of hospitals & clinics for diagnosis and treatment.
  • The market is characterized by a low-to-moderate level of merger and acquisition activity, indicating a landscape characterized by stable competition and a focus on internal development rather than external consolidation.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Diagnostic Method
    • 1.2.2. End-use
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Diagnostic Method Outlook
    • 2.2.2. End-use Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of target disease
      • 3.2.1.2. Technological advancements
      • 3.2.1.3. Growing awareness and screening initiatives
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory hurdles and compliance requirements
      • 3.2.2.2. Underdiagnosis and misdiagnosis
  • 3.3. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Regulatory Scenario
  • 3.5. Reimbursement Scenario
  • 3.6. Pricing Analysis
  • 3.7. Target Population Analysis

Chapter 4. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: Diagnostic Method Estimates & Trend Analysis

  • 4.1. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: Diagnostic Method Segment Dashboard
  • 4.2. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: Diagnostic Method Movement Analysis
  • 4.3. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Size & Trend Analysis, by Diagnostic Method, 2018 to 2030 (USD Million)
  • 4.4. Laboratory Tests
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Indirect Pancreatic Function Tests
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Stool Tests
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Blood Tests
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Other Tests
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Imaging Tests
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. CT Scans
      • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3. MRI
      • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4. Endoscopic Ultrasound for Pancreatic Function Tests
      • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: End-use Estimates & Trend Analysis

  • 5.1. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: End-use Segment Dashboard
  • 5.2. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: End-use Movement Analysis
  • 5.3. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
  • 5.4. Hospitals & Clinics
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Diagnostic Laboratories
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Research Institutes
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Participant Categorization
  • 6.2. Participant Overview
  • 6.3. Financial Performance
  • 6.4. Product Benchmarking
  • 6.5. Heat Map Analysis
  • 6.6. Vendor Landscape
    • 6.6.1. List of key distributors and channel partners
    • 6.6.2. Consumer behavior analysis
    • 6.6.3. ChiRhoClin
      • 6.6.3.1. Company overview
      • 6.6.3.2. Financial performance
      • 6.6.3.3. Product benchmarking
      • 6.6.3.4. Strategic initiatives
    • 6.6.4. Certest Biotec.
      • 6.6.4.1. Company overview
      • 6.6.4.2. Financial performance
      • 6.6.4.3. Product benchmarking
      • 6.6.4.4. Strategic initiatives
    • 6.6.5. ScheBo Biotech AG
      • 6.6.5.1. Company overview
      • 6.6.5.2. Financial performance
      • 6.6.5.3. Product benchmarking
      • 6.6.5.4. Strategic initiatives
    • 6.6.6. Immundiagnostik AG
      • 6.6.6.1. Company overview
      • 6.6.6.2. Financial performance
      • 6.6.6.3. Product benchmarking
      • 6.6.6.4. Strategic initiatives
    • 6.6.7. Laboratory Corporation of America Holdings
      • 6.6.7.1. Company overview
      • 6.6.7.2. Financial performance
      • 6.6.7.3. Product benchmarking
      • 6.6.7.4. Strategic initiatives
    • 6.6.8. Boster Biological Technology
      • 6.6.8.1. Company overview
      • 6.6.8.2. Financial performance
      • 6.6.8.3. Product benchmarking
      • 6.6.8.4. Strategic initiatives
    • 6.6.9. ALPCO Diagnostics
      • 6.6.9.1. Company overview
      • 6.6.9.2. Financial performance
      • 6.6.9.3. Product benchmarking
      • 6.6.9.4. Strategic initiatives
    • 6.6.10. Quest Diagnostics Incorporated
      • 6.6.10.1. Company overview
      • 6.6.10.2. Financial performance
      • 6.6.10.3. Product benchmarking
      • 6.6.10.4. Strategic initiatives
    • 6.6.11. DiaSorin S.p.A.
      • 6.6.11.1. Company overview
      • 6.6.11.2. Financial performance
      • 6.6.11.3. Product benchmarking
      • 6.6.11.4. Strategic initiatives
    • 6.6.12. ARUP Laboratories
      • 6.6.12.1. Company overview
      • 6.6.12.2. Financial performance
      • 6.6.12.3. Product benchmarking
      • 6.6.12.4. Strategic initiatives
    • 6.6.13. Alpha Laboratories
      • 6.6.13.1. Company overview
      • 6.6.13.2. Financial performance
      • 6.6.13.3. Product benchmarking
      • 6.6.13.4. Strategic initiatives
    • 6.6.14. Verisana Laboratories
      • 6.6.14.1. Company overview
      • 6.6.14.2. Financial performance
      • 6.6.14.3. Product benchmarking
      • 6.6.14.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 U.S. Exocrine Pancreatic Insufficiency Diagnostics market revenue estimates and forecast, by Diagnostic Method, 2018 - 2030 (USD Million)
  • Table 4 U.S. exocrine pancreatic insufficiency diagnostics market revenue estimates and forecast, by end-use, 2018 - 2030 (USD Million)
  • Table 5 Laboratory information U.S.
  • Table 6 List of players adopting merger & acquisition strategy
  • Table 7 List of players adopting acquisition strategy
  • Table 8 List of players adopting other strategy

List of Figures

  • Fig. 1 U.S. exocrine pancreatic insufficiency diagnostics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment.
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Diagnostic method and end-use segment snapshot
  • Fig. 10 Competitive landscape snapshot
  • Fig. 11 Market dynamics
  • Fig. 12 Porter's five forces analysis
  • Fig. 13 PESTLE analysis
  • Fig. 14 U.S. Exocrine Pancreatic Insufficiency Diagnostics market: Diagnostic Method outlook and key takeaways
  • Fig. 15 U.S. Exocrine Pancreatic Insufficiency Diagnostics market: Diagnostic Method movement analysis
  • Fig. 16 Laboratory Tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Laboratory Tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
  • Fig. 18 Indirect Pancreatic Function Tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Indirect Pancreatic Function Tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
  • Fig. 20 Stool Tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Stool Tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
  • Fig. 22 Blood Tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Blood Tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
  • Fig. 24 Other tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Other tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
  • Fig. 26 Imaging tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Imaging tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
  • Fig. 28 CT scans market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 CT scans market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
  • Fig. 30 MRI market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Endoscopic ultrasound for pancreatic function tests for pancreatic function tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Endoscopic ultrasound for pancreatic function tests for pancreatic function tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
  • Fig. 33 U.S. exocrine pancreatic insufficiency diagnostics market: By end-use, key takeaways
  • Fig. 34 U.S. exocrine pancreatic insufficiency diagnostics market, by end-use: Market share, 2023 & 2030
  • Fig. 35 Hospitals and clinics market, 2018 - 2030 (USD Million)
  • Fig. 36 Diagnostic laboratories market, 2018 - 2030 (USD Million)
  • Fig. 37 Research institutes market, 2018 - 2030 (USD Million)
  • Fig. 38 Research institutes market, 2018 - 2030 (Number of Tests, '000)
  • Fig. 39 Company/competition categorization
  • Fig. 40 Heat map analysis
  • Fig. 41 Consumer behavior analysis
  • Fig. 42 Exocrine pancreatic insufficiency diagnostics industry key takeaways
  • Fig. 43 Strategy mapping